Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 27, Issue 1, 2012, Pages 15-21

  Ihl, Ralf ^a   Ferris, Steven ^b,c   Robert, Philippe ^d   Winblad, Bengt ^e   Gauthier, Serge ^f   Tennigkeit, Frank ^g  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

^f MCGILL UNIVERSITY   (Canada)

^g MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

ADAS cog; Alzheimer's disease; memantine; mild AD

Indexed keywords

MEMANTINE; PLACEBO;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MENTAL PERFORMANCE; MENTAL TASK; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; ORIENTATION; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; TREATMENT RESPONSE; WORD RECOGNITION;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; COGNITION; COGNITION DISORDERS; DOPAMINE AGENTS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 82955176957     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2679     Document Type: Article

References (17)

1. Bakchine S, Loft H,. 2008. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomized, double-blind, placebo-controlled 6-month study. J Alzheimer's Dis 13: 97-107. (Pubitemid 351365621)
2. Ferris S, Lucca U, Mohs R, et al,. 1997. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 11: 34-38. (Pubitemid 127726418)
3. Harrison JE,. 2001. Cognitive testing and drug development. Clin Res Focus 12: 5-11.
4. Harrison JE,. 2007. Measuring cognitive change in Alzheimer's disease clinical drug trials. The JNHA 11: 327-329. (Pubitemid 47121933)
5. Hobart JC, Cano SL, Zajicek JP, Thompson AI,. 2007. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 6: 1094-1105. (Pubitemid 350116704)
6. Ihl R, Weyer G,. 1993. Die Alzheimer Disease Assessment Scale (ADAS). Beltz Test: Weinheim.
7. Ihl R, Frölich L, Dierks T, Martin EM, Maurer K,. 1992. Differential validity of psychometric tests in dementia of the Alzheimer type. Psychiatry Res 44: 93-106. (Pubitemid 23016246)
8. Ihl R, Grass-Kapanke B, Jaenner M, Weyer G,. 1999. Neuropsychometric tests in cross sectional and longitudinal studies-a regression analysis of ADAS-cog, SKT and MMSE. Pharmacopsychiatry 32: 248-254.
9. Ihl R, Brinkmeyer J, Jänner M, Kerdar MS,. 2000. A comparison of ADAS and EEG in the discrimination of patients with dementia of the Alzheimer type from healthy controls. Neuropsychobiology 41: 102-107. (Pubitemid 30058131)
10. Peskind ER, Potkin SG, Pomara N, et al,. 2006. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14: 704-715. (Pubitemid 44196270)
11. Pomara N, Ott BR, Peskind E, Resnick EM,. 2007. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord 21: 60-64. (Pubitemid 46398957)
12. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT,. 2008. Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5: 83-89. (Pubitemid 351536358)
13. Rosen WG, Mohs RC, Davis KL,. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364.
14. Wesnes KA,. 2008. Assessing change in cognitive function in dementia: The relative utilities of the Alzhrimer's Disease Assessment Scale-cognitive subscale and the cognitive drug research system. Aging 5: 261-263. (Pubitemid 351347867)
15. Wesnes KA, Harrison JE,. 2003. The evaluation of cognitive function in the dementias: methododlogical and regulatory considerations. Dial Clin Neurosci 5: 77-88. (Pubitemid 36806546)
16. Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D,. 1997. Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr 9: 123-138. (Pubitemid 27455497)
17. Wouters H, van Gool WA, Schmand B, Lindeboom R,. 2008. Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 22: 236-244.